相关实验视频
Updated: May 28, 2025

06:07
Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System
Published on: October 22, 2020
6.2K
香烟烟雾有助于MASLD的进展:从分子机制到治疗
Jiatong Xu1, Yifan Li1, Zixuan Feng1
1Queen Mary School, Medical College, Nanchang University, Nanchang 330006, China.
Cells
|February 12, 2025
概括
香烟烟雾 (CS) 通过破坏细胞过程,显著促进与代谢功能障碍相关的脂肪性肝病 (MASLD). 戒烟和天然化合物在逆转CS诱导的肝损伤方面表现有前途,提供新的治疗途径.
科学领域:
- 肝病学和毒理学 肝病学和毒理学
- 分子生物学分子生物学
- 代谢疾病 代谢疾病
背景情况:
- 香烟烟雾 (CS) 含有4000多种化合物,已知会导致细胞损伤.
- 代谢功能障碍相关的脂肪性肝病 (MASLD),以前称为NAFLD,是一种广泛的慢性肝病.
- CS越来越多地与MASLD的发病率和进展有关,需要对其机制的最新理解.
研究的目的:
- 阐明CS促进MASLD的特定信号通路.
- 总结最近关于CS诱导肝损伤逆转因子的发现.
- 为未来的MASLD研究和治疗提供见解.
主要方法:
- 审查现有的关于CS对肝脏新陈代谢影响的科学文献.
- 对参与CS诱导的肝损伤的信号通路的分析.
- 识别和总结影响MASLD的自然化合物和生活方式变化.
主要成果:
- CS 破坏脂质代谢,诱导炎症和亡,并通过多个信号通路促进肝纤维化.
- 目前对于MASLD.没有批准的药物干预措施.
- 改变生活方式,包括戒烟和使用天然成分,可以改善CS诱导的肝病理.
结论:
- 通过各种分子途径,CS是MASLD进展的重要风险因素.
- 戒烟和自然干预措施代表了管理CS相关肝病的有希望的策略.
- 对这些途径和逆转因素的进一步研究对于有效的MASLD治疗至关重要.
更多相关视频
相关概念视频
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
COPD: Pathogenesis and Clinical Features
227
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
227
Asthma: Pathogenesis and Management
341
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
341
COPD: Management Using Bronchodilators and Corticosteroids
174
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
174
Antiasthma Drugs: Leukotriene Modifiers
239
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
239
Drugs Used in Lower Respiratory Disorders: Overview
343
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
343

